BIOMAT Database Logo BIOMAT Database Logo

[Hazards of cytostatic therapy]. 1978

G Petrányi

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

G Petrányi
[Platidiam--advantages and hazards of a new cytostatic].
July 1982, Casopis lekaru ceskych,
G Petrányi
[Cytostatic agents and cytostatic therapy].
September 1973, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
G Petrányi
[Cytostatic therapy].
June 1950, Klinische Medizin; osterreichische Zeitschrift fur wissenschaftliche und praktische Medizin,
G Petrányi
[CYTOSTATIC THERAPY].
January 1964, Geneeskundige bladen uit kliniek en laboratorium voor de praktijk,
G Petrányi
[Adjuvant cytostatic therapy].
February 1978, Lakartidningen,
G Petrányi
[Cytostatic therapy of hemoblastosis].
January 1964, Pharmakotherapia,
G Petrányi
[Cytostatic therapy of psoriasis].
October 1979, Lakartidningen,
G Petrányi
Cytostatic therapy of leukoses.
October 1958, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
G Petrányi
Duration of cytostatic therapy.
June 1985, Lancet (London, England),
G Petrányi
[Criticism of cytostatic therapy].
November 1957, Medizinische Klinik,
Copied contents to your clipboard!